Attruby (acoramidis) / BridgeBio, AstraZeneca, Bayer - LARVOL DELTA

Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World Evidence. (PubMed, Cardiol Ther) - "In this first real-world comparative effectiveness study of newly treated patients, acoramidis had a significantly lower risk of DI events and composite events of DI, HFH, and mortality than tafamidis, potentially supporting improved clinical stability with acoramidis initiation. Additional evaluation with longer follow-up, larger cohorts, and/or prospective clinical outcomes is warranted. Graphical abstract available for this article."

HEOR • Journal • Real-world evidence • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Multiple Myeloma • Oncology

Microscopic Colitis Unmasked: A Treatable Mimic of Gastrointestinal Amyloidosis in Wild-Type ATTR Cardiac Amyloidosis (ACG 2026) - "We present a case of an ATTRwt patient with significant diarrhea found to have biopsy-proven lymphocytic colitis and negative Congo red staining.â¯â¯ Case Description/ An 84-year-old male with ATTRwt cardiac amyloidosis, diagnosed one year prior with a positive technetium pyrophosphate scan and negative genetic testing, now on Acoramidis, presented with chronic non-bloody diarrhea for 2 years...His medications included aspirin, metoprolol, atorvastatin, and pantoprazole...The robust response to budesonide supports microscopic colitis as the most likely etiology. As ATTRwt diagnosis becomes more frequent with increased disease awareness, recognizing co-occurring GI conditions will be essential to avoid misattribution and ensure targeted treatment.⯠Figure: Clinical Timeline: ATTRwt Cardiac Amyloidosis with Co-occurring Lymphocytic Colitis"

Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology

Specific treatment of ATTR-CM in Germany-expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK). (PubMed, Clin Res Cardiol) - "This consensus provides a practical framework for the specific treatment of ATTR-CM in Germany, aiming for early treatment initiation. Local standards and shared decision-making remain essential for the establishment of ATTR-CM therapy in an individual patient."

Journal • Review • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

MOSAIC-TTR: Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy (clinicaltrials.gov) - P=N/A | N=500 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study. (PubMed, J Comp Eff Res) - " Acoramidis was linked to a lower estimated ACM risk in this emulated comparative analysis. These findings should be considered as hypothesis-generating, requiring confirmation in head-to-head studies."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Molecular imaging of TTR amyloidosis: New data. (PubMed, Hell J Nucl Med) - "This narrative review synthesizes recent data on molecular imaging, emphasizing the central role of nuclear medicine physicians in applying multimodality diagnostic algorithms, recognizing typical and equivocal scan patterns. It further explores emerging roles for quantitative SPECT/CT and amyloid PET tracers in monitoring response to disease modifying therapies, including tetramer stabilizers (tafamidis, acoramidis), RNA interference silencers (vutrisiran, patisiran), and investigational fibril targeting antibodies and gene editing strategies, underscoring a shift from purely diagnostic imaging toward dynamic treatment monitoring in ATTR CM."

Journal • Review • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure

Acoramidis Improves Health Status In Patients With Wild-Type And Variant Transthyretin Amyloid Cardiomyopathy: KCCQ Domains Analysis From The ATTRibute-CM Study (HFSA 2026) - "In ATTRibute-CM, acoramidis attenuated the decline in heart failure-related health status vs placebo in participants with ATTRwt-CM and ATTRv-CM, with consistent benefits observed across KCCQ-OS and individual domain scores."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Preparation and performance of antibacterial and bioactive silver nanoparticle/nano-hydroxyapatite gradient composite gel coatings on Ti implants. (PubMed, Colloids Surf B Biointerfaces) - "Notably, the [email protected] composite exhibited the most balanced performance, with an antibacterial rate of 82.27% against Escherichia coli and 81.88% against Staphylococcus aureus...Endothelial cell migration assays showed a 24-hour wound healing rate of approximately 61% for the composite, notably exceeding the 38% of the pure Ti substrate. Combined with in vitro cell culture, the composite demonstrated no cytotoxicity, maintaining day-5 cell proliferation optical density (OD) values consistently higher than those of the pure Ti control."

Journal • Hematological Disorders • Infectious Disease

Oleogel fabrication from Lactobacillus-stabilized emulsion templates: The role of bacterial surface properties in network stabilization mechanisms. (PubMed, Food Res Int) - "In contrast, hydrophilic and electroneutral strains, L. helveticus AG10-1, formed unstable emulsion templates and defective oleogel networks with low hardness (40.81 g) and oil-binding capacity (73.33%)...Mechanistically, bacterial hydrophobicity governed interfacial adsorption and emulsion-template stability, whereas surface charge regulated bacterial distribution and oleogel network architecture. These findings establish a structure-function relationship linking bacterial surface properties to oleogel performance, providing a basis for the rational design of potentially postbiotic-based oleogels and the development of clean-label structured lipid systems for fat substitutes, bakery products, and functional food delivery applications."

Journal • Infectious Disease

Effect Of Acoramidis On Outpatient Worsening Heart Failure In Transthyretin Amyloid Cardiomyopathy: Findings From ATTRibute-CM (HFSA 2026) - P3 | "Outpatient worsening HF was strongly prognostic of other clinical outcomes in participants with ATTR-CM. Acoramidis treatment led to an early and sustained reduction in the risk of outpatient worsening HF and was associated with a reduced risk of ACM/recurrent CVH and of first CVH vs placebo, even after adjusting for time-dependent outpatient worsening HF."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Treatment With Acoramidis Reduces Days Lost To Death And/or Cardiovascular-related Hospitalization, Preserving Time Alive Outside The Hospital In Patients With Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM (HFSA 2026) - "In participants with ATTR-CM, acoramidis reduced DLDCVH vs placebo. Acoramidis preserved a mean of >1 month of time alive outside the hospital (38 days) over 30 months, extending to 65 days over 3 years using observed data and up to 94 days with modeled estimates, reflecting divergence in outcomes over time. This demonstrates acoramidis may reduce hospitalization-related healthcare costs, a key component of healthcare decision-making."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Association Between The Burden Of Cardiovascular-related Hospitalizations And All-cause Mortality In Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM (HFSA 2026) - P3 | "Introduction: In the phase 3 ATTRibute-CM study (NCT03860935), treatment with acoramidis, a novel, oral transthyretin (TTR) stabilizer that achieves near‑complete (≥90%) TTR stabilization, led to a 50% risk reduction in cardiovascular-related hospitalization (CVH) through Month 30, compared with placebo, in participants with transthyretin amyloid cardiomyopathy (ATTR-CM)... In ATTRibute-CM, a higher burden of CVH events was associated with a significantly higher subsequent risk of ACM over 30 months. The association between CVH reduction with effective therapies and improved survival warrants further study."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Acoramidis Preserves Functional Capacity And Quality Of Life In P.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM [Poster no. 605] (HFSA 2026) - No abstract available

HEOR • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Effect Of Acoramidis On Heart Failure-related Health Status Before And After Cardiovascular-related Hospitalization: Insights From ATTRibute-CM [Poster no. 590] (HFSA 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Acoramidis Reduces Risk Of Cardiovascular-related Mortality And Hospitalization In Women With Transthyretin Amyloid Cardiomyopathy [Poster no. 494] (HFSA 2026) - No abstract available

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Real-world Burden Of Transthyretin Amyloid Cardiomyopathy Disease And Outcomes In Patients On Tafamidis Before Switching To Acoramidis [Poster no. 484] (HFSA 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Improvements In Health-related Quality Of Life With Acoramidis In Patients With Wild-Type And Variant Transthyretin Amyloid Cardiomyopathy: An EQ-5D-5L Analysis From ATTRibute-CM [Poster no. 469] (HFSA 2026) - No abstract available

Clinical • HEOR • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM (AHA 2026) - "Abstract is embargoed at this time."

Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

A novel AI-derived digital biomarker for monitoring disease progression in ATTR-CM: first-in-trial use of a computer vision AI-ECG algorithm within a phase 3 pivotal randomized controlled trial (ESC 2026) - P3 | "An image-based AI-ECG algorithm demonstrated discrimination across clinical subgroups at baseline and detected differential longitudinal changes between acoramidis and placebo over 30 months. These findings support the potential role of AI-ECG-derived prediction scores as a scalable digital biomarker for disease monitoring in clinical trials and potential routine cardiovascular care."

Biomarker • Clinical • P3 data • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM (ESC 2026) - P3 | "Treatment with acoramidis resulted in significant and clinically meaningful benefits in HRQoL in both ATTRwt-CM and ATTRv-CM. Greater impact on HRQoL vs placebo was observed in participants with ATTRv-CM."

Clinical • HEOR • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study (ESC 2026) - "In ATTRibute-CM, acoramidis attenuated the decline in heart failure-related health status vs placebo in participants with ATTRwt-CM and ATTRv-CM, with consistent benefits observed across KCCQ-OS and individual domain scores."

Clinical • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Do tafamidis and acoramidis improve survival and cardiovascular outcomes in transthyretin amyloid cardiomyopathy? a systematic review and meta-analysis (ESC 2026) - "TTR-stabilizing therapy delivers clinically meaningful, statistically compelling reductions in death and cardiovascular morbidity for patients with ATTR-CM. These findings support early screening for amyloid cardiomyopathy, routine initiation of tafamidis where available, and rapid completion of ongoing acoramidis trials to expand access and potentially transform the natural history of this once-inexorable disease."

Retrospective data • Review • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension (ESC 2026) - "These M54 findings extend the survival benefit and favourable biomarker trends previously reported at M30, demonstrating the long-term durability of efficacy and safety of acoramidis in ATTRv-CM, including in the p.V142I subgroup."

Clinical • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in participants with ATTR-CM: results from ATTRibute-CM (ESC 2026) - "In participants with ATTR-CM, acoramidis reduced DLDCVH vs placebo. Acoramidis preserved more than 1 month of time alive outside the hospital (38 days) over 30 months, with benefits extending to 65 days over 3 years using observed data and up to 94 days with modelled estimates, reflecting progressive divergence in outcomes over time. This demonstrates that acoramidis may reduce hospitalization-related healthcare costs, which are a key component of healthcare decision-making."

Clinical • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

Impact of serum transthyretin levels during disease-modifying therapy with tafamidis on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy (ESC 2026) - "Background: The ATTRIBUTE-CM trial, which evaluated the efficacy of the transthyretin (TTR) tetramer stabilizer acoramidis, demonstrated that baseline serum transthyretin (sTTR) levels and early increases in sTTR predict long-term prognosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Baseline sTTR levels and ΔTTR during tafamidis therapy may serve as promising prognostic biomarkers in patients with ATTR-CM. Serial TTR monitoring may provide clinically meaningful information for evaluating disease progression and therapeutic response during tafamidis treatment."

Clinical • Atrial Fibrillation • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure